About EuTxGNN

EuTxGNN is a drug repurposing prediction system for European Medicines Agency (EMA) approved drugs, powered by the TxGNN framework.


About the Developer

This platform is developed and operated by 藥提醒科技有限公司 (yao.care, company registration number 83620786, 12F, No. 220, Sec. 2, Taiwan Blvd., West Dist., Taichung City, Taiwan).

EuTxGNN is the the European Union site of the company’s “TxGNN Drug Repurposing” product line. The same system is deployed across 30 countries and regions, each named {CC}TxGNN (JpTxGNN, UsTxGNN, DETxGNN, and so on) at {cc}txgnn.yao.care. Product overview: https://www.yao.care/medical/txgnn/.

The TxGNN model itself was developed by the Zitnik Lab at Harvard Medical School and published in Nature Medicine. This platform is the production system 藥提醒科技有限公司 built on top of that model, covering national drug-registration data integration, dual knowledge-graph and deep-learning prediction, PubMed / ClinicalTrials evidence grading, and SMART on FHIR electronic health record integration.


What is Drug Repurposing?

Drug repurposing (also known as drug repositioning) is the process of identifying new therapeutic uses for existing approved drugs. This approach offers several advantages:

  • Reduced Development Time: Existing drugs have known safety profiles
  • Lower Costs: Bypasses early-stage development
  • Higher Success Rates: Known pharmacokinetics and toxicology

The TxGNN Model

TxGNN is a graph neural network model developed for drug repurposing, published in Nature Medicine (2023).

Key Features

  • Knowledge Graph Integration: Combines multiple biomedical databases
  • Graph Neural Networks: Learns drug-disease relationships from network structure
  • Explainable AI: Provides interpretable predictions with supporting evidence

EuTxGNN Pipeline

EMA Data → Drug Normalization → DrugBank Mapping → TxGNN Prediction → FHIR Output

Data Processing

  1. EMA Medicines Database: Download authorized human medicines
  2. Article 57 Database: Additional pharmaceutical product data
  3. Drug Normalization: Standardize drug names to INN format
  4. DrugBank Mapping: Map to DrugBank identifiers

Prediction

  1. Knowledge Graph (KG): Network-based association discovery
  2. Deep Learning (DL): Neural network score prediction
  3. Evidence Integration: Combine with clinical trial and literature data

Output

  1. FHIR Resources: Standardized clinical data format
  2. Web Interface: Browse predictions online
  3. SMART App: EHR integration capability

Data Sources

Source Description Update Frequency
EMA Medicines Centrally authorized medicines Daily
Article 57 EU pharmaceutical submissions Periodic
TxGNN KG Biomedical knowledge graph Static (2023)
DrugBank Drug database Periodic

Technical Stack

  • Python 3.12+: Core processing
  • TxGNN: Prediction model
  • FHIR R4: Clinical data standard
  • Jekyll: Documentation site
  • GitHub Actions: CI/CD

Limitations

  • Predictions are computational and require clinical validation
  • Limited to drugs with DrugBank mappings
  • Based on TxGNN model trained on US data
  • Not all EMA drugs have sufficient data for prediction

Contact

For questions or feedback, please open an issue on the project repository.


License

This project is for research purposes only. See the repository for license details.


Copyright © 2026 藥提醒科技有限公司 (yao.care). For research purposes only. Not medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.